Immunic appoints ex-Roche neuroscience head Skerjanec to board; 150K options granted

IMMUNIC, INC.

Simona Skerjanec appointed to board effective July 22, 2024 as Class I director until 2027 annual meeting.
Received inducement grant for 100K shares ($1.46) vesting monthly over 3 years; additional 50K shares vesting over 1 year.
Board size increased from 7 to 8 members.
Skerjanec led Roche's Ocrevus commercial launch, generating over $1B in first 10 months.
Company approaching late-stage readouts for vidofludimus calcium in MS; recently hired ex-Novartis/Biogen COO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Simona Skerjanec

Director

IMUX · IMMUNIC, INC.

Effective: 2024-07-22
Filed: July 24, 2024, 7:59 PM ET

On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Simona Skerjanec was appointed as Director at IMMUNIC, INC..

Action: appointed
Role: Director

Exact text from the filing

On July 24, 2024, Immunic, Inc. (the “Company”) announced the appointment of Simona Skerjanec, M.Pharm, MBA, as a member of the board of directors (the “Board”) of the Company, effective as of July 22, 2024.

View on SEC.gov

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-24-000957

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.